Literature DB >> 12143968

The Kudo elbow prosthesis in rheumatoid arthritis: a consecutive series of 26 elbow replacements in 24 patients followed prospectively for a mean of 5 years.

Hans Rahme1.   

Abstract

The Kudo prosthesis is the most commonly used elbow implant in Sweden. However, there are few reports of the results, besides those reported by Kudo himself. I have implanted 30 Kudo type 4 or 5 elbow prostheses in 28 patients with rheumatoid arthritis. 3 arthroplastics were revised, 2 because of loosening and 1 because of a periprosthetic ulnar fracture. 6 major peroperative or early postoperative complications occurred, but only 1 of these was a failure. 2 patients developed postoperative ulnar neuropathy, one was transient and the other patient died 1 year after surgery. 26 elbows were available for follow-up at an average 5 (2-8) years after implantation. All 26 functioned well although radiographic loosening of the humeral component was found in 1 patient. The average range of flexion increased by 14 degrees while the extension lag was unchanged (35 degrees). Activities of daily living had improved markedly and all but 3 patients were satisfied with their elbow. Radiolucent lines were seen around the proximal part of the ulnar component in 18/26 elbows. Although progressive in 1 patient only, this is a matter of concern, indicating that this component may be the weak part of the Kudo prosthesis.

Entities:  

Mesh:

Year:  2002        PMID: 12143968     DOI: 10.1080/000164702320155202

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  2 in total

Review 1.  Systematic review of primary total elbow prostheses used for the rheumatoid elbow.

Authors:  J C T van der Lugt; P M Rozing
Journal:  Clin Rheumatol       Date:  2004-04-16       Impact factor: 2.980

2.  Long-term results of the iBP elbow prosthesis: beware of destructive metallosis!

Authors:  Daniëlle Meijering; Alexander L Boerboom; Fred Breukelman; Denise Eygendaal; Sjoerd K Bulstra; Martin Stevens
Journal:  BMC Musculoskelet Disord       Date:  2019-09-06       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.